|

Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • BioInvent International AB1

Indications

  • Advanced Malignancies1
  • T - Cell Lymphoma1
  • Melanoma1
  • Ovarian Cancer1
  • Cancer1

Duarte, California1 trial

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

City of Hope National Medical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.